Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Dare Bioscience, Inc. | ceru-10q_20160930.htm |
| EX-32.2 - EX-32.2 - Dare Bioscience, Inc. | ceru-ex322_171.htm |
| EX-32.1 - EX-32.1 - Dare Bioscience, Inc. | ceru-ex321_6.htm |
| EX-31.2 - EX-31.2 - Dare Bioscience, Inc. | ceru-ex312_7.htm |
| EX-31.1 - EX-31.1 - Dare Bioscience, Inc. | ceru-ex311_8.htm |
| EX-10.3 - EX-10.3 - Dare Bioscience, Inc. | ceru-ex103_507.htm |
| EX-10.2 - EX-10.2 - Dare Bioscience, Inc. | ceru-ex102_394.htm |
EXHIBIT 10.1
November 1, 2016
Gregg Beloff, Principal
Danforth Advisors, LLC
91 Middle Road
Southborough, MA 01772
Dear Gregg:
This letter is in reference to the Consulting Agreement between Cerulean Pharma Inc. ("Cerulean") and Danforth Advisors, LLC dated May 27, 2015 (as amended, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meaning given such terms in the Agreement.
In accordance with recent discussions, and consistent with the nonqualified stock option granted to you individually on August 22, 2016, this letter is to document our agreement to further extend the term of the Agreement through August 30, 2018. All other terms of your agreement remain unchanged, and in full force and effect.
If you agree to this extension, please sign below where your name appears and return one fully executed copy to me.
|
|
|
Very truly yours, |
|
|
|
|
|
|
|
CERULEAN PHARMA INC |
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Alejandra Carvajal |
|
|
|
Alejandra Carvajal |
|
|
|
Vice President, General Counsel |
|
Agreed to: |
|
|
|
|
|
|
|
Danforth Advisors, LLC |
|
|
|
|
|
|
|
By: /s/ Gregg Beloff, Managing |
|
|
|
Gregg Beloff, Managing Director |
|
|
Cerulean Pharma Inc. | 35 Gatehouse Drive I Waltham, MA 02451 1 P: 781-996-4300 1 F: 844-894-2378